Evidence map›Paper›PMID 38527187›Full record

ReviewChemistry (Weinheim an der Bergstrasse, Germany)2024

Secondary Sites of the C-type Lectin-Like Fold.

Jonathan Lefèbre, Torben Falk, Yunzhan Ning, Christoph Rademacher

Abstract readReview
In one paragraph

Review in Chemistry (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Synthetic Ligands of Myeloid C-Type Lectin Receptors.Chembiochem : a European journal of chemical biology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jonathan LefèbreDepartment of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-8505-2181
Torben FalkDepartment of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-9737-7055
Yunzhan NingDepartment of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-6879-786X
Christoph RademacherDepartment of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-7082-7239

Funding

Austrian Science Fund FWF I 5157European Research Council 716024H2020 European Research Council 956314Österreichische Forschungsförderungsgesellschaft 10.55776/I5157Vienna Science and Technology Fund 10.47379/LS21039
6 · The paper itself

Abstract

C-type lectins are a large superfamily of proteins involved in a multitude of biological processes. In particular, their involvement in immunity and homeostasis has rendered them attractive targets for diverse therapeutic interventions. They share a characteristic C-type lectin-like domain whose adaptability enables them to bind a broad spectrum of ligands beyond the originally defined canonical Ca

Indexed as

Lectins, C-TypeAntigens, CDBinding SitesCalciumCell Adhesion MoleculesDC-Specific ICAM-3 Grabbing NonintegrinDectin-1HumansLigandsMannose-Binding LectinMannose-Binding LectinsNK Cell Lectin-Like Receptor Subfamily KProtein BindingReceptors, Cell SurfaceAntigens, CDCalciumCD207 protein, humanCell Adhesion MoleculesDC-Specific ICAM-3 Grabbing NonintegrinDectin-1Lectins, C-TypeLigandsMannose-Binding LectinMannose-Binding LectinsMGL lectin, humanNK Cell Lectin-Like Receptor Subfamily KReceptors, Cell Surface

Identifiers

PMID38527187
PMCPMC7618208

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.